The

Team

 MirZyme is built by a team of committed and experienced individuals working at the forefront of medical research and business.

Management Team

Asif Ahmed

Chairman and  CEO

Asif Ahmed is the founder of MirZyme and a world-renowned British scientist who discovered two protective pathways that can be used to predict, prevent and treat preeclampsia.

Mike Vousden 2_edited.jpg

Mr Mike Vousden

Financial Director

Mike Vousden has been a chartered accountant for over 25 years. He is responsible for all the financial aspects of the company.

May Rezai_edited.jpg

Dr May Rezai

Operations Lead

May Rezai obtained her PhD in 2021 and has been working with MirZyme from its inception. She is also the Chair of a UK-wide community based charity.

Headshot AAH.jpg

Dr Allyah Abbas-Hanif

Clinical Development Lead

Allyah Abbas-Hanif is an experienced pharmaceutical physician with more than a decade of proficiency in taking drugs from concept to global markets. She is trained in cardiology with an interest in maternal health.

Non Executive Directors

Prof. Julia King

Non-Executive

Julia Elizabeth King, Baroness Brown of Cambridge, DBE FREng FRS is a British
engineer and crossbench member of the House of Lords. She was a managing director at Rolls Royce and a member of the governing board of the European Institute of Innovation and Technology.

Sami Ahmad

Mr Sami Ahmad

Non-Executive

Sami Ahmad is CFO of Trecora Resources, a public NYSE-listed (TREC) leading
company in chemicals based in Houston, Texas. Sami has an MBA in finance from the University of Chicago.

Wenda

Dr Wenda Ramma

Non-Executive

Wenda Ramma has a Ph.D. in Vascular Biology and an Executive MBA from the UCLA. Wenda is the Medical Science Liason (Cardiovascular) at Bristol-Myers Squibb. At Amgen Wenda supported the launch of Repatha and other cardiovascular products.

Malcolm headshot.jpeg

Dr Malcolm Barratt-Johnson

Non-Executive

Malcolm Barratt-Johnson is a Physician Scientist and the past president of the Royal Society of Medicine (Pharmaceutical Medicine). He is a lead medical assessor for MHRA and EMA. Malcolm is the MD of PharmaMedic Consultancy Limited.

 
 

Advisors

Kevin

Mr Kevin Holland

Commercial Advisor

Kevin Holland is a health adviser helping Life Sciences companies gain market
access, patient access and commercialisation for new therapies. He was the head at Baxter’s leading a $600m business.

Duncan

Dr Duncan McHale

Clinical Advisor

Duncan McHale is supporting MirZyme's strategy and the clinical development of the
pipeline of therapeutics. He was the head of Translational Sciences at AstraZeneca.

Jane

Mrs Jane de Vries

Product Valuation Advisor

Jane has 17 years of pharmaceutical experience at GSK where she was a Senior Director and Value Evidence Leader within GSK’s global Value Evidence and Outcomes function, focussing on global payer and patient value evidence generation.

Keqing Wang_edited_edited.jpg

Dr Keqing Wang

Scientific Advisor

Keqing Wang is a Vascular Scientist with clinical experience of Chinese hospitals. She was involved in the development of anticancer drug PEP005 which was later acquired by LEO Pharma for $2.875 billion.